DARE · Dare Bioscience Inc. Common Stock
View on chartInsiders & Stakes
| Robin Joan Steele Director | ▲ Buy | Grant | 47,055 Shares held | 6/30/2026 | View profile |
| William H. Rastetter Director | ▲ Buy | Grant | 39,721 Shares held | 6/30/2026 | View profile |
| Gregory W. Matz Director | ▲ Buy | Grant | 30,847 Shares held | 6/30/2026 | View profile |
| Jessica D. Grossman Director | ▲ Buy | Grant | 26,066 Shares held | 6/30/2026 | View profile |
| Susan L. Kelley Director | ▲ Buy | Grant | 23,696 Shares held | 6/30/2026 | View profile |
Transaction History
| Jessica D. Grossman | ▲ Buy | Grant | 26,066 | $0 | 6/30/2026 |
| Susan L. Kelley | ▲ Buy | Grant | 23,696 | $0 | 6/30/2026 |
| Gregory W. Matz | ▲ Buy | Grant | 30,805 | $0 | 6/30/2026 |
| William H. Rastetter | ▲ Buy | Grant | 38,862 | $0 | 6/30/2026 |
| Robin Joan Steele | ▲ Buy | Grant | 26,540 | $0 | 6/30/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
DARE Receives New Patents for HPV and Cervical Treatments
Dare Bioscience announced it has secured a U.S. patent for its HPV treatment program, which could position the company as a first pharmacologic option for HPV infection. The company also received a patent covering topical formulations of lopinavir and ritonavir for cervical pathologies. These approvals strengthen the company’s pipeline and may support future regulatory progress.
DARE Receives New Patents for HPV and Cervical Treatments. Dare Bioscience announced it has secured a U.S. patent for its HPV treatment program, which could position the company as a first pharmacologic option for HPV infection. The company also received a patent covering topical formulations of lopinavir and ritonavir for cervical pathologies. These approvals strengthen the company’s pipeline and may support future regulatory progress.